January 31st, 2020 by Tyler Scott | NAACCReview Home Leave a comment






 Announcing CiNA Volume 5 – Cancer Prevalence in the United States and Canada

On January 1, 2016, there were an estimated 360,000 persons in Canada and over 8 million persons living in the U.S. with a history of a cancer diagnosis in the previous 10 years.

These statistics are the most comprehensive estimates of cancer prevalence to date for U.S. and Canadian jurisdictions and can be found in the inaugural Cancer in North America (CiNA) prevalence volume: Cancer in North America: 2012–2016 Volume Five: Cancer Prevalence in the United States and Canada 2006–2015.

Cancer prevalence estimates can assist state and local public health and care practitioners in anticipating health-care needs and resource allocation. This addition to the annual CiNA publications was born out of a need for a more comprehensive representation of cancer prevalence in the United States and Canada. Historically, U.S. cancer prevalence has been estimated using data from SEER 9 and SEER 13 registries, covering approximately 9.4% and 14% of the U.S. population, respectively. CiNA Prevalence includes data from 9 of 13 Canadian provinces or territories and 45 of 51 U.S. states or the District of Columbia, so 38% of Canada and 92% of U.S. national population coverage.

For all sites combined, 10-year limited duration (LD) prevalence was estimated to be 2.66% in the U.S. and 2.61% in Canada. Among persons aged 65 years and older, 10-year LD prevalence was estimated to be 9.89% in both the U.S. and Canada. In the U.S., prevalence by race varied from 3.28% among non-Hispanic whites to 2.07% among non-Hispanic blacks to 1.19% among Hispanics.

By primary site category, the highest 10-year LD prevalence was for prostate (1.087%) and female breast (1.077%). The third most common site was colorectal, with 10-year LD prevalence of 0.240%.

For all sites combined, higher 10-year LD prevalence was found in the U.S. Northeast and eastern Canadian provinces, with prevalence > 3.25% in Maine, New Brunswick, New Hampshire, Newfoundland, Nova Scotia, and Vermont. Lower prevalence rates were observed in the U.S. West and western Canada; in Alaska, Alberta, Los Angeles, Northwest Territories, Texas, and Utah 10-year LD prevalence was estimated at < 2.2%.

Variation in prevalence by registry catchment area can be due to several factors, including, differences in population demographic characteristics related to age, race, ethnicity, and SES; differences in cancer risk behaviors and exposures; cancer screening rates; access to and quality of care; and cancer registration practices that impact case ascertainment, date of diagnosis and follow-up.

The addition of a Prevalence Monograph to the CiNA publications moves surveillance efforts and public health professionals one step closer to accessing local information that can benefit resource allocation and planning for their communities. Public health practitioners, health officials, and researchers can reference the CiNA Prevalence volume to access additional registry jurisdiction-specific estimates of 2-, 5-, and 10-year cancer prevalence by race/ethnicity, sex, and primary site.



Johnson CJ, Mariotto A, Qiao B, Huang B, Morawski B, Turner D, Weir H, Ellison L, Sherman R, Wilson R, Firth R (eds). Cancer in North America: 2012-2016 Volume Five: Cancer Prevalence in the United States and Canada 2006-2015. Springfield, IL: North American Association of Central Cancer Registries, Inc. January 2020.




  1. Understanding cancer prevalence statistics.
  2. Limited-duration prevalence.
  3. Registry Groupings in SEER Data and Statistics.


Full Report, HERE

Report Overview:

CiNA Volume Five: Cancer Prevalence in the United States and Canada 2006-2015 includes data from 59 registries
on more than 8 million cases diagnosed among North Americans between 2006 and 2015.
Volume Five is comprised of two data sections:
Section two includes two, five, and ten year limited-duration prevalence counts and prevalence percentages and
confidence intervals for the United States, Canada and North America combined. These statistics are presented
for all races by sex and select cancer sites. The tables for each cancer site present statistics by a total and specific
age groups for each region. In the United States combined, prevalence statistics for non-Hispanic whites, non Hispanic Blacks, and Hispanics are also presented.
Section three includes two, five, and ten year limited-duration prevalence counts and prevalence percentages and
confidence intervals by registry, sex and select cancer sites. Prevalence statistics are available for the United States
and Canadian registries by all races and for the United States registries for non-Hispanic whites, non-Hispanic
Blacks, and Hispanics.
Special thanks go to Steve Scoppa and Rick Firth, Information Management Services, Inc., who prepared the
analytic dataset used for this report; members of the NAACCR Prevalence Volume Task Force, who authored
this first edition of the CiNA Prevalence Volume; and all of the registry staff who contributed data.



Copyright © 2018 NAACCR, Inc. All Rights Reserved | naaccr-swoosh-only See NAACCR Partners and Sponsors